Related Experiment Video
Updated: Nov 2, 2025
06:01
Expression of Transgenes in Native Bladder Urothelium Using Adenovirus-Mediated Transduction
Published on: October 6, 2022
1.6K
Gene Therapy for Overactive Bladder: A Review of BK-Channel α-Subunit Gene Transfer
Karl-Erik Andersson1, George Joseph Christ2, Kelvin P Davies3
1Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Therapeutics and Clinical Risk Management
|June 11, 2021
Summary
Gene therapy using URO-902 shows promise for treating overactive bladder (OAB). This novel approach leverages the big potassium (BK) channel to restore bladder function with a favorable safety profile.
Area of Science:
- Urology
- Gene Therapy
- Molecular Biology
Background:
- Overactive bladder (OAB) requires localized treatments with minimal side effects.
- Gene therapy offers a potential strategy to restore normal bladder function by targeting cellular physiology.
Purpose of the Study:
- To review the potential of gene therapy for OAB treatment, focusing on URO-902.
- To evaluate the safety and efficacy of URO-902, a gene therapy targeting the big potassium (BK) channel.
Main Methods:
- Literature search on PubMed for BK channel function and gene transfer for OAB.
- Inclusion of preclinical and clinical trial data (Phase 1 and 2) for URO-902 in erectile dysfunction and OAB.
Main Results:
- URO-902 is the first gene therapy targeting the BK channel for OAB in clinical trials.
- No serious treatment-related adverse events were reported in URO-902 studies.
- Promising secondary efficacy endpoints indicated improvements in OAB symptoms and quality of life.
Conclusions:
- Gene therapy with URO-902 demonstrates encouraging safety and efficacy in women with OAB.
- Further investigation into URO-902 for OAB treatment is warranted.
